报告分别用两种预处理方案进行异基因骨髓移植治疗３３例恶性血液病的疗效和毒性。预处理方案１为分次全身照射１３．５Ｇｙ和环磷酰胺６０ｍｇ·ｋｇ￣（－１）·ｄ￣（－１）×２天，１１例患者的４年复发率可能为４７％，非复发死亡率２７％，预处理方案相关毒性（ＲＲＴ）可耐受；预处理方案２在前者基础上加用卡氮芥３００ｍｇ／ｍ￣２×１天和足叶乙甙（Ｖｐ１６）３００ｍｇ·ｍ￣（－２）·ｄ￣（－１）×２天，１５例接受ＨＬＡ相合同胞供髓（其中２例为第２次移植）者，保险统计的３年生存、无病生存和复发率可能分别为４０％、４０％和１４％，１００日内无ＲＲＴ致死者；７例接受ＨＬＡ相合无关献髓者中１例因ＲＲＴ致死，粘膜炎常见。结论是对于恶性血液病，分次ＴＢＩ１３．５Ｇｙ＋ＣＢＶ（环磷酰胺、卡氮芥、Ｖｎ１６）方案是抗白血病活性高和ＲＲＴ低的预处理方案。 The report reported the efficacy and toxicity of 33 allogeneic hematologic diseases with allogeneic bone marrow transplantation using two pretreatment protocols. For pretreatment protocol 1, 13.5 Gy of total systemic irradiation and 60 mg · kg -1 (-1) xd -1 of cyclophosphamide for 2 days, the 4-year relapse rate of 11 patients was 47% The mortality rate was 27%, and the RRT of the pretreatment regimen was tolerable. The pretreatment regimen 2 was based on the former with 300 mg / m ~ 2 × 1 day of carmustine and 300 mg · m ~ (-2) · d ~ (-1) × 2 days, 15 cases of HLA-matched sibling donor (2 cases of which were the second transplant), insurance statistics of 3-year survival, disease-free survival and recurrence rates may be Were 40%, 40% and 14%, respectively. There were no RRT deaths within 100 days. One patient died of RRT due to RRT in 7 of the 7 patients who accepted HLA donation, and mucositis was common. The conclusion is that, for hematologic malignancies, the sub-program of TBI13.5Gy + CBV (cyclophosphamide, carmustine, Vn16) is a pretreatment program with high leukemia activity and low RRT.